DE60041250D1 - Multivalenter dengue-virus impfstoff - Google Patents

Multivalenter dengue-virus impfstoff

Info

Publication number
DE60041250D1
DE60041250D1 DE60041250T DE60041250T DE60041250D1 DE 60041250 D1 DE60041250 D1 DE 60041250D1 DE 60041250 T DE60041250 T DE 60041250T DE 60041250 T DE60041250 T DE 60041250T DE 60041250 D1 DE60041250 D1 DE 60041250D1
Authority
DE
Germany
Prior art keywords
dengue
virus
dengue virus
virus vaccine
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60041250T
Other languages
English (en)
Inventor
Kenneth H Eckels
Joseph R Putnak
Doria R Dubois
Bruce L Innis
Charles H Hoke
Sun Wellington
Kanesa-Thasan Niranjan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Army
Walter Reed Army Institute of Research
Original Assignee
US Department of Army
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Army, Walter Reed Army Institute of Research filed Critical US Department of Army
Application granted granted Critical
Publication of DE60041250D1 publication Critical patent/DE60041250D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60041250T 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff Expired - Fee Related DE60041250D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11
PCT/US2000/008199 WO2000057907A2 (en) 1999-03-26 2000-03-24 Multivalent dengue virus vaccine

Publications (1)

Publication Number Publication Date
DE60041250D1 true DE60041250D1 (de) 2009-02-12

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041250T Expired - Fee Related DE60041250D1 (de) 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff

Country Status (12)

Country Link
US (2) US6638514B1 (de)
EP (1) EP1165127B1 (de)
JP (1) JP2002540168A (de)
KR (1) KR100721745B1 (de)
CN (1) CN1191092C (de)
AT (1) ATE419006T1 (de)
AU (1) AU779280B2 (de)
CA (1) CA2368674A1 (de)
DE (1) DE60041250D1 (de)
ES (1) ES2322327T3 (de)
MX (1) MXPA01009683A (de)
WO (1) WO2000057907A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
EP2290109B1 (de) 2001-05-22 2014-08-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Entwicklung von zur Attenuierung von Dengue-Viren geeigneten Mutationen und chimäre Dengue-Viren
ATE475706T1 (de) 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
BRPI0613328A2 (pt) * 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
KR20110127637A (ko) * 2008-12-22 2011-11-25 칠드런스리서치인스티튜트 패혈증 검출 방법
US9265821B2 (en) 2009-02-17 2016-02-23 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ618158A (en) 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
EP2384761B1 (de) * 2010-05-07 2013-09-04 Deutsches Krebsforschungszentrum Modifiziertes Nagetier-Parvovirus, das sich durch menschliche Glioma vermehren und ausbreiten kann
CN105246506A (zh) * 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
SG11201704942QA (en) 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
CA2991212A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
WO2017053873A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
CA3082779A1 (en) * 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP3598865A4 (de) * 2017-03-08 2021-04-07 University of Georgia Research Foundation, Inc. Verfahren und zusammensetzungen in zusammenhang mit erhöhter viraler produktion
SG11201912163WA (en) * 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
CA2163550A1 (en) 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
CA2269213A1 (en) * 1996-10-28 1998-05-07 The University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン

Also Published As

Publication number Publication date
KR100721745B1 (ko) 2007-05-25
WO2000057907A9 (en) 2002-04-11
US20070087015A1 (en) 2007-04-19
CN1191092C (zh) 2005-03-02
MXPA01009683A (es) 2003-06-24
EP1165127A2 (de) 2002-01-02
JP2002540168A (ja) 2002-11-26
AU779280B2 (en) 2005-01-13
WO2000057907A2 (en) 2000-10-05
ATE419006T1 (de) 2009-01-15
CN1351502A (zh) 2002-05-29
US7217418B2 (en) 2007-05-15
KR20020008136A (ko) 2002-01-29
US6638514B1 (en) 2003-10-28
EP1165127B1 (de) 2008-12-31
WO2000057907A3 (en) 2001-04-12
ES2322327T3 (es) 2009-06-19
AU4038200A (en) 2000-10-16
CA2368674A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
Ghosh et al. Dengue vaccines: challenges, development, current status and prospects
PH12018502175A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
MX2009012299A (es) Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue.
EA200900297A1 (ru) Ингибиторы вируса гепатита с
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
PE20020474A1 (es) Compuestos peptidomimeticos como inhibidores de la serina proteasa ns3 del virus de hepatitis c
ATE503764T1 (de) Inhibitoren des hepatitis-c-virus
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MY180698A (en) Immunization protocol against the 4 dengue serotypes
PL373398A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
Botting et al. Novel approaches to flavivirus drug discovery
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
DE69940769D1 (de) Orale flüssige zusammensetzungen
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MY169275A (en) Method of immunization against the four serotypes of dengue
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
JP2002540168A5 (de)
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee